Vernalis (LON:VER) - Cough/cold portfolio on track
Aug 10th 2012 - Edison Investment Research today published a report on Vernalis (VER.L, LSE:VER, LON:VER) entitled "Cough/cold Portfolio On Track". In summary, the report says:
Vernalis’s alliance with Tris Pharma to develop up to six extended release cough/cold products for the US prescription market may prove to be the transformational event that delivers sustainable profitability. Exact timelines are uncertain; although the first products could be approved in time for the 2014/15 winter cough and cold season. Planning for the creation of the US sales force has begun, with recruitment likely just ahead of product approval. Further in-licensing efforts will now focus on products that complement the seasonality of the current portfolio.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
